HutchMed CEO On Novel Drug Pricing Strategy In China
Prospects After New Approval, HK Listing
Executive Summary
A successful IPO on the Hong Kong Stock Exchange will jump-start the company’s R&D and new drug approvals, says HutchMed's CEO in an interview.
You may also be interested in...
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.